Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03376659
Title Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Georgetown University
Indications

colorectal adenocarcinoma

pancreatic adenocarcinoma

Therapies

Capecitabine + CV301 + Durvalumab

Bevacizumab + Capecitabine + CV301 + Durvalumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.